- Home
- AHG vs GHRS Comparison
AHG vs GHRS Comparison
Compare AHG & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- GHRS
- Stock Information
- Founded
- AHG 2013
- GHRS 2018
- Country
- AHG China
- GHRS Ireland
- Employees
- AHG N/A
- GHRS N/A
- Industry
- AHG Business Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- GHRS Health Care
- Exchange
- AHG Nasdaq
- GHRS Nasdaq
- Market Cap
- AHG 752.4M
- GHRS 892.0M
- IPO Year
- AHG N/A
- GHRS 2021
- Fundamental
- Price
- AHG $1.51
- GHRS $14.38
- Analyst Decision
- AHG
- GHRS Strong Buy
- Analyst Count
- AHG 0
- GHRS 9
- Target Price
- AHG N/A
- GHRS $30.11
- AVG Volume (30 Days)
- AHG 10.4K
- GHRS 407.8K
- Earning Date
- AHG 12-15-2025
- GHRS 11-06-2025
- Dividend Yield
- AHG N/A
- GHRS N/A
- EPS Growth
- AHG N/A
- GHRS N/A
- EPS
- AHG N/A
- GHRS N/A
- Revenue
- AHG $14,777,798.00
- GHRS N/A
- Revenue This Year
- AHG N/A
- GHRS N/A
- Revenue Next Year
- AHG N/A
- GHRS N/A
- P/E Ratio
- AHG N/A
- GHRS N/A
- Revenue Growth
- AHG 512.09
- GHRS N/A
- 52 Week Low
- AHG $0.74
- GHRS $6.72
- 52 Week High
- AHG $2.35
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- AHG 45.04
- GHRS 55.96
- Support Level
- AHG $1.33
- GHRS $13.71
- Resistance Level
- AHG $1.56
- GHRS $15.01
- Average True Range (ATR)
- AHG 0.09
- GHRS 0.98
- MACD
- AHG 0.00
- GHRS 0.04
- Stochastic Oscillator
- AHG 35.94
- GHRS 74.17
About AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.